Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 416

Document Document Title
WO/2004/020443A1
A method for manufacturing hydrogen sulphate (alpha S) of the alpha-(2-chlorophenyl)-6,7­dihydro-thieno[3,2-c]pyridine-5( 4H)-acetic acid methyl ester (clopidogrel hydrogen sulphate) of formula I, in crystalline Form I, wherein the comp...  
WO2003066638A3
Ecteinascidin compounds with a quinone ring for ring E are active as anti-cancer agents. Related processes and compounds are provided.  
WO/2003/066638A2
Ecteinascidin compounds with a quinone ring for ring E are active as anti−cancer agents. Related processes and compounds are provided.  
WO2003051362A3
Provided are new crystalline Forms III, IV, V and VI of clopidogrel hydrogensulfate and the amorphous form of clopidogrel hydrogensulfate, as well as their pharmaceutical compositions, and method of treatments with such compositions. Als...  
WO/2003/064432A1
Intermediates for the total synthesis of ecteinascidins which are represented by the general formula (2) and bear the skeletal pentacyclic structure of ecteinascidins, characterized in that the 4-position OH group and trichloroethoxycarb...  
WO/2003/051362A2
Provided are new crystalline Forms III, IV, V and VI of clopidogrel hydrogensulfate and the amorphous form of clopidogrel hydrogensulfate, as well as their pharmaceutical compositions, and method of treatments with such compositions. Als...  
WO/2003/039571A1
Improved dosing schedules for ecteinascidin 743 are given for treatment of cancer.  
WO/2003/032999A1
A compound of Formula (I) or a pharmaceutical acceptable salt thereof, or a tautomer thereof, wherein G¿1?, G¿2?, and B are as defined in the application, are selective inhibitors of MMP-13. The compounds are useful for treating diseas...  
WO/2003/025017A1
A crystalline composition comprising a crystal of the IL-6 receptor I chain is provided. Also provided are methods of using the crystal and related structural information to screen for and design compounds that interact with IL-6R, or va...  
WO/2003/020731A1
The invention relates to novel substituted, annelated indole and heteroindole derivatives of general formula (I), to tautomers, stereoisomers, mixtures and pharmaceutically acceptable salts thereof and to the production and use thereof a...  
WO2002028865A3
Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents._In particular, the invention relates to compounds that are potent and selective inhibitors of cyclic guanosine 3'...  
WO/2003/014127A1
Derivatives of ecteinascidin 736 of general formula (I) wherein the groups R¿1?, R¿2?, R¿3?, R¿4? and R¿5? are each independently selected from the group consisting of H, OH, OR', SH, SR', SOR', SO¿2?R', C(=O)R', C(=O)OR', NO¿2?, ...  
WO/2003/008423A1
Derivatives of Et-743 or Et-770 or Et-729 are provided. The derivatives are of the general formula (Ia) wherein the substituent groups take various permitted meanings.  
WO/2002/100865A1
The present invention relates to benzoxazepine derivative having the general formula I, wherein X represents CO or SO¿2?; R?1¿, R?2¿, R?3¿ and R?4¿ are independently selected from H, (C¿1-4?)alkyl, (C¿1-4?)alkyloxy, (C¿1-4?)alkyl...  
WO/2002/064843A1
The present invention provides a bacterial symbiont of Ecteinascidia turbinata, and methods for the synthesis of an ecteinascidin.  
WO/2002/046197A1
This invention is directed to macroheterocyclic compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.  
WO/2002/028865A2
Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents._In particular, the invention relates to compounds that are potent and selective inhibitors of cyclic guanosine 3'...  
WO/2002/020015A1
The present invention is directed to piperidine- and pyrrolidine-containing macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherape...  
WO/2001/087894A1
Antitumour compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected fro...  
WO/2001/087895A1
Processes are provided for preparing compounds with a fused ring structure of formula (XIV). Such products include ecteinascidins and have a spiroamine-1,4-bridge. The process involving forming a 1,4 bridge using a l-labile, 10-hydroxy, ...  
WO/2001/077114A1
The present invention is directed to peptidomimetic macrocyclic compounds that inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions contain...  
WO/2001/077115A1
Compounds having a fused ecteinascidin five ring system with a 1,4 bridge having the structure of formula (VIa or VIb) and compounds in which the -NH¿2? or -OH of the 1,4 bridge is derivatised are disclosed. Such compounds are useful in...  
WO2001028992A3
There is provided compounds of formula (I), wherein R<1>, R<2>, R<3>, R<4>, R<41> to R<46>, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial ...  
WO/2001/051125A1
The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions contai...  
WO/2001/051128A1
The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions contai...  
WO/2001/028992A2
There is provided compounds of formula (I), wherein R?1¿, R?2¿, R?3¿, R?4¿, R?41¿ to R?46¿, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular a...  
WO2000069862A3
Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically: R<1> is an amidomethylene group or an ac...  
WO/2001/018006A1
The present invention is directed to macrocyclic compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing th...  
WO/2000/069441A1
ET743 is used in the preparation of a medicament for the treatment of the human body for cancer.  
WO/2000/069862A2
Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically: R?1¿ is an amidomethylene group or an a...  
WO/2000/034278A1
Novel triazolo derivatives including the one represented by formula (26), and pharmacologically acceptable salts thereof; and chemokine inhibitors containing the same as the active ingredient. These compounds are useful as remedies for a...  
WO/2000/003722A1
Novel thiazolyl peptide antibiotic compounds, including nocathiacin I, II and III, are disclosed. Also, novel microorganism ATCC-202099 is disclosed.  
WO1999051238A9
The present invention is directed to several newly prepared semi-synthetic ecteinascidin (Et) species, designated herein as Et 757, Boc-Et 729, Iso-Et 743, Et 875, and Et 1560. The physical properties of these compounds, their preparatio...  
WO/2000/001382A1
The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions contai...  
WO/2000/001701A1
The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions contai...  
WO/1999/064426A1
The current invention discloses useful bicyclic and tricyclic amidino derivative compounds represented by Formula (I), pharmaceutical compositions containing these novel compounds, and to their use as nitric oxide synthase inhibitors.  
WO/1999/058125A1
The purification and structure elucidation of several products of the metabolism of Et 743 by human cytochrome CYP3A4 have been accomplished. These compounds are abbreviated herein as 'ETM' followed by a numeric value which represents th...  
WO/1999/051238A1
The present invention is directed to several newly prepared semi-synthetic ecteinascidin (Et) species, designated herein as Et 757, Boc-Et 729, Iso-Et 743, Et 875, and Et 1560. The physical properties of these compounds, their preparatio...  
WO/1998/046080A1
Five new nucleophile substituted ecteinascidin (Et) compounds have been isolated from extracts of $i(Ecteinascidia turbinata). These compounds have been purified by chromatographic techniques and their structures and bioactivities have b...  
WO/1998/012198A1
The present invention is directed to a synthetic process for the formation of ecteinascidin compounds and related structures, such as the saframycins. In one particularly preferred embodiment, the present invention provides a synthetic r...  
WO/1998/007727A1
Compounds having formula (I), wherein R�1? is acyl of formula -C(O)R�2? wherein R�2? is C�1-6? alkyl, C�2-6? alkenyl, C�2-6? alkynyl or aryl; or R�1? is C�2-8? alkenyl or C�2-8? alkynyl, each of which is optionally subs...  
WO/1997/048705A1
A series of compounds for blocking calcium activated potassium channels in rat sympathetic neurones and other mammalian cells, and a method for producing them. These compounds with general formulae (I) and (II), where A and B are spacing...  
WO/1996/030377A1
Novel macrocyclic compounds are constructed to include large cyclic structures that are interrupted by at least one ring sytem. Each interrupting ring system includes two bridgehead atoms. Bridgehead atoms are bonded to one or more bridg...  
WO/1995/029894A1
The invention relates to antimicrobial 5-(N-heterosubstituted amino) quinolone compounds having a structure according to formula (I) or (II), wherein: (1) R1, R2, R3, R9 and R10 form any of a variety of quinolone and related heterocyclic...  
WO1992019613A3
PCT No. PCT/FR92/00392 Sec. 371 Date Dec. 27, 1993 Sec. 102(e) Date Dec. 27, 1993 PCT Filed Apr. 30, 1992 PCT Pub. No. WO92/19613 PCT Pub. Date Nov. 12, 1992.The present invention relates to therapeutic compositions based on compounds ch...  
WO/1992/019613A2
Therapeutical compositions based on compounds selected from formulas (I) and (Ia), wherein X is selected from =S, =O, =SO, =N-OH, =N-R5, =N-NH-CONH2, =N-NH-CSNH2 and (a); A is selected from group (b), a group having formula (c), a C=O gr...  
WO/1992/009607A1
Ecteinascidins 722 and 736 (Et's 722 and 736) have been isolated from the Caribbean tunicate Ecteinascidia turbinata and their structures have been assigned as tetrahydro-beta-carboline-substituted bis(tetrahydro-isoquinolines) related t...  
WO1987007610A3
Novel compounds ecteinascidins 729, 743, 745, 759A, 759B, and 770 having antibacterial and antitumor properties.  
WO/1988/000826A1
Antitumor polycyclic organic compositions and derivatives thereof, a process of producing the compositions and a method for inhibiting tumors utilizing the compositions. More particularly, the compositions are derived from marine organis...  
WO/1987/007610A2
Novel compounds ecteinascidins 729, 743, 745, 759A, 759B, and 770 having antibacterial and antitumor properties.  

Matches 151 - 200 out of 416